Archived Comments for:
Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study
1. On page 2, in the 'Study population and sample size' section, it states that patients were excluded if they were found to 'use of ICS within 30 days preceding this study enrolment'. Is this a typing error for oral, rectal and parental GCS? Since the point of the study was to compare existing asthma medication (some of which used ICS) with Symbicort SMART.
2. On page 3, is Figure 1 'Symbicort Turbuohaler' a spelling error for Symbicort Turbuhaler?
3. On page 4, in the 'Patients' demographics and baseline characteristics' section, is 'Fluticason' a spelling error for Fluticasone?
Judging by the 4 resubmission versions from the pre-publication history, I am shocked that these concerns were not picked up by the reviewers.
Queries regarding SMARTASIA study
6 March 2015
1. On page 2, in the 'Study population and sample size' section, it states that patients were excluded if they were found to 'use of ICS within 30 days preceding this study enrolment'. Is this a typing error for oral, rectal and parental GCS? Since the point of the study was to compare existing asthma medication (some of which used ICS) with Symbicort SMART.
2. On page 3, is Figure 1 'Symbicort Turbuohaler' a spelling error for Symbicort Turbuhaler?
3. On page 4, in the 'Patients' demographics and baseline characteristics' section, is 'Fluticason' a spelling error for Fluticasone?
Judging by the 4 resubmission versions from the pre-publication history, I am shocked that these concerns were not picked up by the reviewers.
Competing interests
None